Flag of the European Union EU Clinical Trials Register Help

Clinical trials for burkitt-lymphoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    35 result(s) found for: burkitt-lymphoma. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2011-003487-75 Sponsor Protocol Number: CARMEN Start Date*: 2011-10-03
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: Phase II trial on safety and activity of intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt's lymphoma.
    Medical condition: Burkitt's lymphoma in HIV-positive patients.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006595 Burkitt's lymphoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003141-16 Sponsor Protocol Number: HEM2012BL01 Start Date*: 2012-10-18
    Sponsor Name:VU University Medical Center
    Full Title: Efficacy and feasibility of first-line treatment with risk-adapted dose-adjusted EPOCH-R (DA-EPOCH-R) in patients with Burkitt lymphoma. A phase II clinical trial.
    Medical condition: Burkitt lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10006596 Burkitt's lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006154-97 Sponsor Protocol Number: 148/2006/U/Sper Start Date*: 2007-01-09
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: HEMOS ALL 0105 Intensification therapy of mature B-ALL, Burkitt and Burkitt like and other HIgh Grade Non-Hodgkinﾒs Lymphoma in Adults
    Medical condition: B-ALL, Burkitt and Burkitt like and Non-Hodgkinﾒs Lymphoma in Adults
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006595 Burkitt's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004394-27 Sponsor Protocol Number: HO127 Start Date*: 2014-06-23
    Sponsor Name:HOVON Foundation
    Full Title: Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma
    Medical condition: High risk Burkitt Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000013123 10006605 Burkitt's tumor or lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-002654-39 Sponsor Protocol Number: HO130 Start Date*: 2015-02-25
    Sponsor Name:HOVON Foundation
    Full Title: A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U
    Medical condition: MYC positive diffuse large B cell lymphoma and Burkitt lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004943 10012819 Diffuse large B-cell lymphomas HLT
    20.0 100000004943 10006596 Burkitt's lymphomas HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004555-16 Sponsor Protocol Number: M20-429 Start Date*: 2022-04-25
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms
    Medical condition: Relapsed/refractory Burkitt's or Burkitt-like lymphoma/leukemia, Diffuse large B-cell lymphoma , or other aggressive mature (CD20+) B-cell lymphomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10006596 Burkitt's lymphomas HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-003479-19 Sponsor Protocol Number: UCL/05/134 Start Date*: 2006-02-02
    Sponsor Name:University College London
    Full Title: A Phase II Single Arm Study of the use of CODOX-M/IVAC with Rituximab (R-CODOX-M/IVAC) in the treatment of patients with Diffuse Large B-Cell Lymphoma (DLBCL) or Burkitt's Lymphoma (BL) of Internat...
    Medical condition: Diffuse large B-cell lymphoma Burkitt's lymphoma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006595 Burkitt's lymphoma PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019224-31 Sponsor Protocol Number: IGR2009/1593 Start Date*: 2012-06-06
    Sponsor Name:Institut Gustave Roussy
    Full Title: INTERGROUP TRIAL FOR CHILDREN OR ADOLESCENTS WITH B-CELL NHL OR B-AL: EVALUATION OF RITUXIMAB EFFICACY AND SAFETY IN HIGH RISK PATIENTS
    Medical condition: untreated advanced stage B-cell NHL or B-AL.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006595 Burkitt's lymphoma PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067194 Burkitt's leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) ES (Temporarily Halted) NL (Completed) HU (Completed) IT (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001833-87 Sponsor Protocol Number: 00600 Start Date*: 2008-06-20
    Sponsor Name:University Medical Center Freiburg
    Full Title: Use of Palifermin to reduce the duration, frequency and severity of oral mucositis after high dose therapy with BEAM and autologous peripheral blood stem cell transplantation in patients with malig...
    Medical condition: malign lymphoma (primary high risks patients: - therapy refractory / relapsed NHL - therapy refractory / relapsed M. Hodgkin - Burkitt-NHL
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006595 Burkitt's lymphoma LLT
    9.1 10029609 Non-Hodgkin's lymphoma unspecified histology aggressive recurrent LLT
    9.1 10029610 Non-Hodgkin's lymphoma unspecified histology aggressive refractory LLT
    9.1 10020328 Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001697-17 Sponsor Protocol Number: R1979-ONC-1504 Start Date*: 2015-12-01
    Sponsor Name:Regeneron Pharmaceuticals, Inc
    Full Title: A Phase 1 Study to Assess Safety and Tolerability of REGN1979, an anti-CD20 x anti- CD3 bispecific monoclonal antibody, and REGN2810, an anti-programmed death-1 monoclonal antibody, in Patients wit...
    Medical condition: B-cell malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003917 B-cell type acute leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026945 Mature B-cell type acute leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067184 Burkitt's leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003890 B precursor type acute leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020267 Hodgkin's disease refractory PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020266 Hodgkin's disease recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003902 B-cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2005-001067-64 Sponsor Protocol Number: BURKIMAB007/04 Start Date*: 2005-07-25
    Sponsor Name:PETHEMA Foundation
    Full Title: Multicentre study of optimization of therapy in mature B-cell acute lymphoblastic leukemia and Burkitt's lymphoma in adults (over 15 years)
    Medical condition: Adults B-ALL and Burkitt´s Lymphoma
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004526-28 Sponsor Protocol Number: BMT-CTN#1101 Start Date*: 2015-06-17
    Sponsor Name:National Institutes of Health/National Heart, Lung and Bood Institute
    Full Title: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow ...
    Medical condition: patients eligible for a hematopoietic stem cell transplantation with a diagnosis of: 1)Acute lymphoblastic leukemia/lymphoma, acute myelogenous leukemia, or Burkitt’s lymphoma in remission. 2)Lym...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    16.1 100000004864 10024330 Leukemia acute LLT
    16.1 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    16.1 10005329 - Blood and lymphatic system disorders 10025321 Lymphomas non-Hodgkin's T-cell HLGT
    16.1 10005329 - Blood and lymphatic system disorders 10006596 Burkitt's lymphomas HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005843-21 Sponsor Protocol Number: KT-US-982-5968 Start Date*: 2022-02-08
    Sponsor Name:KITE PHARMA INC.
    Full Title: Long-term Follow-up Study for Participants of Kite Sponsored Interventional Studies Treated With Gene-Modified Cells
    Medical condition: B-cell malignancies and Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026801 Mantle cell lymphoma refractory PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008977 Chronic lymphocytic leukemia recurrent LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008978 Chronic lymphocytic leukemia refractory LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065856 Non-Hodgkin's lymphoma unspecified histology indolent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060558 Acute myeloid leukemia recurrent LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081514 Acute myeloid leukemia refractory LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063621 Acute lymphoblastic leukaemia recurrent LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006599 Burkitt's lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036714 Primary mediastinal large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005010-30 Sponsor Protocol Number: KTE-C19-104 Start Date*: 2017-09-27
    Sponsor Name:Kite Pharma, Inc.
    Full Title: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4)
    Medical condition: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) SE (Completed) BE (Completed) PL (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000704-28 Sponsor Protocol Number: GCP#05.01.020 Start Date*: 2016-06-16
    Sponsor Name:Gamida Cell Ltd
    Full Title: A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Progenitor Cells, versus Unmanipulated Umbilical Cord...
    Medical condition: High risk haematological malignancies
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    19.0 100000004864 10000886 Acute myeloid leukemia LLT
    19.0 100000004864 10009015 Chronic myeloid leukemia LLT
    19.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) PT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-010824-25 Sponsor Protocol Number: DSHNHL 2008-R6 Start Date*: 2010-04-12
    Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation-Hämatologie und Onkologie mbH
    Full Title: Open-label, Multicenter Phase I/II Study: Salvage Therapy of Progressive and Relapsed Aggressive Non-Hodgkin-Lymphoma by Combination of Lenalidomide (Revlimid®) with Rituximab, Dexamethason, High-d...
    Medical condition: Patients with relapsed or primary progressive aggressive non-Hodgkin's lymphoma. These lymphomas comprise: 1. Follicular lymphoma grade III (FL III°) 2. Diffuse large B cell lymphoma (DLBCL), all v...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-005019-15 Sponsor Protocol Number: CCTL019C2202 Start Date*: 2018-11-08
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A Phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (N...
    Medical condition: pediatric and adolescents patients with CD19positive r/r mature B-cell NHL who have relapsed after one or more prior therapies or are primary refractory.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) DE (Completed) SE (Ongoing) DK (Completed) NO (Completed) AT (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002961-36 Sponsor Protocol Number: EFC11603 Start Date*: 2013-02-11
    Sponsor Name:Sanofi-aventis recherche et développement
    Full Title: Phase II two stage dose finding run-in study of SAR3419, an anti-CD19 antibody-maytansine conjugate,administered as a single agent by intravenous infusion in patients with relapsed or Refractory Ac...
    Medical condition: Acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000846 Acute lymphocytic leukaemia PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-005477-54 Sponsor Protocol Number: TrRaMM Start Date*: 2007-12-03
    Sponsor Name:OSPEDALE S. RAFFAELE DI MILANO
    Full Title: Treosulfan-based conditioning and Rapamycin-base GvHD prophylaxis prior to un-manipulated allogeneic haematopoietic stem cell transplantation from a mismatched donor in patients with high risk haem...
    Medical condition: neoplastic and haematologic patologies
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10057677 Transplant PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000227-71 Sponsor Protocol Number: ITCC-059 Start Date*: 2016-09-02
    Sponsor Name:Erasmus Medical Center
    Full Title: A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia
    Medical condition: pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) IE (Trial now transitioned) AT (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) CZ (Ongoing) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) IT (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) PT (Prematurely Ended) BE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 07:05:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA